Pfizer is leaving no stone unturned in its efforts to prevent Novo Nordisk from stealing off with Metsera, the weight-loss therapy developer it is hoping to acquire in a deal worth up to $7.3 billion.
New! Sign up for our free email newsletter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results